Skip to main content

Table 1 Baseline and stimulation characteristics of patients in group without (Group A) and with (Group B) pretreatment with Myo-inositol

From: Pretreatment with myo-inositol in non polycystic ovary syndrome patients undergoing multiple follicular stimulation for IVF: a pilot study

  No myo-inositol Yes myo-inositol p
Group A Group B
N = 50 N = 50
No. of patients 50 50  
Age (year) 33.3 ± 2.8 34.4 ± 3.4 0.09
BMI 22.9 ± 3.3 22.7 ± 2.6 0.88
FSH (mIU/ml), basal 7.3 ± 1.5 7.2 ± 2 0.35
LH (mIU/ml), basal 4.7 ± 2 4.9 ± 2 0.87
17β-estradiol (E2) (pg/ml), 47.2 ± 17.8 43.6 ± 12.7 0.20
basal    
FSH (mIU/ml), down 4.7 ± 1.5 4.6 ± 2.2 0.87
regulation    
LH (mIU/ml), down 1.6 ± 0.9 2.7 ± 1.1 <0.01
regulation    
17β-estradiol (E2) (pg/ml), 26.4 ± 20 24.4 ± 14.5 0.31
down regulation    
rFSH treatment days 11.7 ± 1.8 11.8 ± 1.5 0.64
Total rFSH dose (IU) 2,479 ± 979 2,084 ± 648 <0.05
E2 (pg/ml), day of hCG 1,312 ± 629 1,516 ± 640 0.12
Total length of stimulation 11.7 ±1.8 11.8 ± 1.5 0.64